• Bayer raised EUR 3 billion in equity capital via an agreement with Apollo-managed funds to strengthen its capital structure.
• The investment targets a newly created entity holding Bayer’s long-acting reversible contraceptives business within its Pharmaceuticals division.
• Apollo will take a minority, non-controlling stake; Bayer will keep a majority stake and full operational control.
• The LARC business will remain fully consolidated in Bayer’s group financial statements; closing expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollo Global Management Inc. published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.